Gujarat Themis Biosyn Ltd Stock Price Today (NSE: GUJTHEM)
Fundamental Score
Gujarat Themis Biosyn Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Gujarat Themis Biosyn Ltd share price today is ₹226.90, down 6.10% on NSE/BSE as of 30 March 2026. Gujarat Themis Biosyn Ltd (GUJTHEM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹4.45K (Cr). The 52-week high for GUJTHEM share price is ₹479.00 and the 52-week low is ₹222.05. At a P/E ratio of 92.24x, GUJTHEM is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 21.69% and a debt-to-equity ratio of 0.27.
Gujarat Themis Biosyn Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Gujarat Themis Biosyn Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Gujarat Themis Biosyn Share Price: A Financial Stability Analysis
The pharmaceutical industry is experiencing a wave of innovation, yet faces increasing scrutiny regarding pricing pressures and regulatory compliance. This analysis evaluates the financial stability of Gujarat Themis Biosyn Ltd, with its current share price at ₹323.8999938964844, and forms part of an extensive 80-parameter fundamental audit verified by Sweta Mishra. This is an observational review and does not constitute investment advice.
Gujarat Themis Biosyn's current Price-to-Earnings (PE) ratio stands at 92.24. This is significantly higher than the average PE ratio observed across the broader market, suggesting that investors have high expectations for future earnings growth. However, relative to its peers, a high PE ratio might indicate overvaluation and warrants careful consideration. Comparing to
Mankind Pharma Ltd, while both operate in the pharmaceutical sector, differences in management quality and business strategy likely contribute to varying market valuations. Examining factors such as capital allocation efficiency and strategic decision-making are crucial when benchmarking against peers like Mankind Pharma Ltd.One positive indicator is the company's Return on Capital Employed (ROCE) of 27.29%. This figure indicates that Gujarat Themis Biosyn is generating a healthy return on the capital it has invested in its operations. A robust ROCE, if sustained, can contribute to the company's economic moat by enabling it to reinvest profits into expanding its operations, developing new products, or acquiring competitors. This advantage can help maintain its competitive position within the market. However, it is important to observe how effectively this high return is sustained in future business cycles.
Finally, when assessing the financial stability of Gujarat Themis Biosyn, further analysis is needed. Comparison to other sector peers, such as Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd, on metrics like debt levels, revenue growth, and profitability margins, is essential. This deeper examination, combined with an ongoing assessment of the macroeconomic environment, is important for a comprehensive understanding of the risks and opportunities associated with Gujarat Themis Biosyn.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Gujarat Themis Biosyn Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GUJTHEM across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (21.69%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (27.29%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (47.49%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (34.91%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (21.98%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (12.12% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (16.18% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (16.17% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.27)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (222.97x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (70.86%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
2 factors identified
Premium Valuation Risk (P/E: 92.24x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Institutional Interest (FII+DII: 4.12%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Gujarat Themis Biosyn Ltd Financial Statements
Comprehensive financial data for Gujarat Themis Biosyn Ltd including income statement, balance sheet and cash flow
About GUJTHEM (Gujarat Themis Biosyn Ltd)
Gujarat Themis Biosyn Ltd is a dynamic pharmaceutical company rooted in India, specializing in the meticulous manufacture of pharmaceuticals and crucial medicinal chemicals. Instea...d of merely producing drugs, Gujarat Themis Biosyn serves as a pivotal partner in the pharmaceutical supply chain, offering its extensive manufacturing capabilities on a job work basis to other entities operating within India. This model allows the company to maximize resource efficiency and contribute significantly to the wider availability of vital medicines throughout the region. By focusing on this area, Gujarat Themis Biosyn supports the healthcare ecosystem, enabling other companies to meet market demands without the burden of extensive in-house manufacturing infrastructure. The company’s product portfolio features an array of specialized pharmaceutical intermediates. Rifamycin-S takes center stage, a crucial component utilized in medications targeting a range of debilitating conditions. The portfolio includes Mycobacterium avium complex, leprosy, and Legionnaires’ disease. Additionally, they manufacture Rifamycin-O, essential for treating common ailments like traveler’s diarrhea and more complex disorders such as irritable bowel syndrome and hepatic encephalopathy. Gujarat Themis Biosyn also produces Lovastatin, a key ingredient in medicines aimed at managing cholesterol levels and promoting cardiovascular health. The company's dedication to producing these specialized ingredients highlights its role in contributing to both routine treatments and addressing critical health challenges. Established in 1981 and headquartered in Mumbai, Gujarat Themis Biosyn Ltd has cultivated a robust presence in the Indian pharmaceutical sector. Over the decades, the company has refined its manufacturing expertise and strengthened its commitment to quality and innovation. The company has positioned itself as a reliable source for bulk drug manufacturing and pharmaceutical intermediates, fostering trust and collaboration with its clients. The Mumbai headquarters serves as a central hub for overseeing its operations, guiding strategic decisions, and maintaining a steadfast commitment to improving health outcomes through pharmaceutical excellence.
Company Details
Key Leadership
Corporate Events
GUJTHEM Share Price: Frequently Asked Questions
What is the current share price of Gujarat Themis Biosyn Ltd (GUJTHEM)?
As of 30 Mar 2026, 12:05 pm IST, Gujarat Themis Biosyn Ltd share price is ₹226.90. The GUJTHEM stock has a market capitalisation of ₹4.45K (Cr) on NSE/BSE.
Is GUJTHEM share price Overvalued or Undervalued?
GUJTHEM share price is currently trading at a P/E ratio of 92.24x, compared to the industry average of 31.77x. Based on this relative valuation, the Gujarat Themis Biosyn Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of GUJTHEM share price?
The 52-week high of GUJTHEM share price is ₹479.00 and the 52-week low is ₹222.05. These values are updated daily from NSE/BSE price data.
What factors affect the Gujarat Themis Biosyn Ltd share price?
Key factors influencing GUJTHEM share price include quarterly earnings growth (Sales Growth: 21.98%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Gujarat Themis Biosyn Ltd a good stock for long-term investment?
Gujarat Themis Biosyn Ltd shows a 5-year Profit Growth of 16.17% and an ROE of 21.69%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.27 before investing in GUJTHEM shares.
How does Gujarat Themis Biosyn Ltd compare with its industry peers?
Gujarat Themis Biosyn Ltd competes with major peers in the Pharmaceuticals. Investors should compare GUJTHEM share price P/E of 92.24x and ROE of 21.69% against the industry averages to determine competitive standing.
What is the P/E ratio of GUJTHEM and what does it mean?
GUJTHEM share price has a P/E ratio of 92.24x compared to the industry average of 31.77x. Investors pay ₹92 for every ₹1 of annual earnings.
How is GUJTHEM performing according to Bull Run's analysis?
GUJTHEM has a Bull Run fundamental score of 68.9/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does GUJTHEM belong to?
GUJTHEM operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Gujarat Themis Biosyn Ltd share price.
What is Return on Equity (ROE) and why is it important for GUJTHEM?
GUJTHEM has an ROE of 21.69%, which indicates excellent management efficiency. ROE measures how efficiently Gujarat Themis Biosyn Ltd generates profits from shareholders capital.
How is GUJTHEM debt-to-equity ratio and what does it indicate?
GUJTHEM has a debt-to-equity ratio of 0.27, which indicates conservative financing with low financial risk.
What is GUJTHEM dividend yield and is it a good dividend stock?
GUJTHEM offers a dividend yield of 0.16%, meaning you receive ₹0.16 annual dividend for every ₹100 invested in Gujarat Themis Biosyn Ltd shares.
How has GUJTHEM share price grown over the past 5 years?
GUJTHEM has achieved 5-year growth rates of: Sales Growth 12.12%, Profit Growth 16.17%, and EPS Growth 16.18%.
What is the promoter holding in GUJTHEM and why does it matter?
Promoters hold 70.86% of GUJTHEM shares, with 3.30% pledged. High promoter holding often indicates strong management confidence in Gujarat Themis Biosyn Ltd.
What is GUJTHEM market capitalisation category?
GUJTHEM has a market capitalisation of ₹4454 crores, placing it in the Small-cap category.
How volatile is GUJTHEM stock?
GUJTHEM has a beta of N/A. A beta > 1 suggests the Gujarat Themis Biosyn Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is GUJTHEM operating profit margin trend?
GUJTHEM has a 5-year average Operating Profit Margin (OPM) of 47.49%, indicating the company's operational efficiency.
How is GUJTHEM quarterly performance?
Recent quarterly performance shows Gujarat Themis Biosyn Ltd YoY Sales Growth of 21.98% and YoY Profit Growth of 34.91%.
What is the institutional holding pattern in GUJTHEM?
GUJTHEM has FII holding of 2.95% and DII holding of 1.17%. Significant institutional holding often suggests professional confidence in the Gujarat Themis Biosyn Ltd stock.